Eary J F, Conrad E U, Bruckner J D, Folpe A, Hunt K J, Mankoff D A, Howlett A T
University of Washington Medical Center, Seattle 98195-6113, USA.
Clin Cancer Res. 1998 May;4(5):1215-20.
The purpose of this study was to determine the relationship between sarcoma tumor grade and the quantitative tumor metabolism value for [F-18]fluorodeoxyglucose (FDG) determined by positron emission tomography (PET) imaging. Seventy patients with bone or soft-tissue sarcomas underwent PET scanning with quantitative determination of tumor FDG metabolic rate (MRFDG) before treatment. MRFDG (micromol/g/min) for each tumor was compared with National Cancer Institute tumor grade, S-phase percentage, and percentage of aneuploidy of the tumor population. The pretreatment quantitative determination of tumor MRFDG by PET correlates strongly with tumor grade but not with the other selected histopathological tumor correlates. In addition, overlap of MRFDG PET values with tumor grade suggests that PET, an objective tumor measurement, may provide an alternative means of assessing tumor biological potential or may have the potential to overcome some of the limitations of traditional pathological evaluation. FDG PET can uniquely provide a metabolic profile of a diverse group of sarcomas noninvasively and provide clinically relevant tumor biological information.
本研究的目的是确定肉瘤肿瘤分级与通过正电子发射断层扫描（PET）成像测定的[F-18]氟脱氧葡萄糖（FDG）定量肿瘤代谢值之间的关系。70例骨或软组织肉瘤患者在治疗前接受了PET扫描，并对肿瘤FDG代谢率（MRFDG）进行了定量测定。将每个肿瘤的MRFDG（微摩尔/克/分钟）与美国国立癌症研究所肿瘤分级、S期百分比以及肿瘤群体的非整倍体百分比进行比较。PET对肿瘤MRFDG的治疗前定量测定与肿瘤分级密切相关，但与其他选定的肿瘤组织病理学相关因素无关。此外，MRFDG PET值与肿瘤分级的重叠表明，PET作为一种客观的肿瘤测量方法，可能提供一种评估肿瘤生物学潜能的替代手段，或者有可能克服传统病理评估的一些局限性。FDG PET能够独特地无创提供一组不同肉瘤的代谢概况，并提供与临床相关的肿瘤生物学信息。
